Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026 Oct 21, 2026 04:05PM
Revolution Medicines starts Phase 3 trial of zoldonrasib for lung cancer Oct 20, 2026 08:01AM
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastati Oct 20, 2026 08:00AM
Revolution Medicines' daraxonrasib gets positive EU panel opinion Oct 15, 2026 09:46AM
Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer Oct 15, 2026 09:45AM


Oct 5, 2026 08:01AM Revolution Medicines starts Phase 3 trial of drug combo for pancreatic cancer
Oct 5, 2026 08:00AM Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Sep 14, 2026 04:06PM FDA grants breakthrough therapy status to Revolution Medicines drug for pancreatic cancer
Sep 14, 2026 04:05PM Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
Aug 26, 2026 12:59PM FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
Aug 26, 2026 12:59PM U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Aug 10, 2026 06:00AM BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
Aug 1, 2023 07:01AM Revolution Medicines (RVMD) to Acquire EQRx, Inc. (EQRX) in All-Stock Transaction
Aug 1, 2023 07:00AM Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital